SANTA MONICA, Calif., April 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced the availability of an investor-focused corporate synopsis on its English language website, http://en.aidapharma.com/, which may be downloaded as a pdf document. The synopsis details Aida Pharmaceuticals, Inc.'s public company financial information, current product line, the drugs in its development pipeline, as well as its future growth avenues. About Aida Pharmaceuticals Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, Inc., in operation since March 1999, is headquartered in Hangzhou, the People's Republic of China (the "PRC") with manufacturing, distribution and sales points throughout mainland China. Aida Pharmaceuticals, Inc. is GMP certified in the PRC and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Contact Information: Ashley Hull (310) 450-9100 opt 1 Broker Contact: Chesapeake Group (410) 825-3930 Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Ashley Hull, +1-310-450-9100, opt 1, ; or broker contact, Chesapeake Group, +1-410-825-3930, both for Aida Pharmaceuticals, Inc. Web site: http://en.aidapharma.com/

Copyright